Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Shares Shorted: Short Interest Up 69.8% in October

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT – Get Free Report) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 152,917 shares, a growth of 69.8% from the October 15th total of 90,040 shares. Approximately 6.8% of the company’s shares are short sold. Based on an average trading volume of 6,760,367 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on LABT shares. Wall Street Zen downgraded Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, November 7th. HC Wainwright started coverage on Lakewood-Amedex Biotherapeutics in a report on Wednesday, October 28th. They issued a “buy” rating on the stock. Finally, Weiss Ratings raised shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold”.

Read Our Latest Report on LABT

Lakewood-Amedex Biotherapeutics Price Performance

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.06 on Monday, hitting $0.22. The company had a trading volume of 789,942 shares, compared to its average volume of 7,484,873. Lakewood-Amedex Biotherapeutics has a 1 year low of $0.17 and a 1 year high of $98.20. The stock’s 50 day simple moving average is $0.99. The firm has a market capitalization of $519,978.00 and a PE ratio of -0.05.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share (EPS) for the quarter. As a group, analysts anticipate that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current year.

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics is a biotechnology company focused on developing treatments for bacterial infections, including infections caused by drug-resistant pathogens. Its research centers on bisphosphocins, a class of investigational antimicrobial compounds. The company’s activities are primarily research and development; its investigational compounds should not be confused with approved medicines or commercially available products. Publicly available information about its specific product pipeline, operating geographies and leadership is limited.

See Also

Receive News & Ratings for Lakewood-Amedex Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakewood-Amedex Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.